CY1123033T1 - Σπειροκυκλικοι αναστολεις της καθεψινης c - Google Patents
Σπειροκυκλικοι αναστολεις της καθεψινης cInfo
- Publication number
- CY1123033T1 CY1123033T1 CY20191101154T CY191101154T CY1123033T1 CY 1123033 T1 CY1123033 T1 CY 1123033T1 CY 20191101154 T CY20191101154 T CY 20191101154T CY 191101154 T CY191101154 T CY 191101154T CY 1123033 T1 CY1123033 T1 CY 1123033T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cathepsin
- spirocyclic
- inhibitors
- dipeptidyl
- peptidase
- Prior art date
Links
- 102000005600 Cathepsins Human genes 0.000 title 1
- 108010084457 Cathepsins Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000003902 Cathepsin C Human genes 0.000 abstract 1
- 108090000267 Cathepsin C Proteins 0.000 abstract 1
- 229940122524 Cathepsin C inhibitor Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184613 | 2014-09-12 | ||
| PCT/EP2015/070449 WO2016038007A1 (en) | 2014-09-12 | 2015-09-08 | Spirocyclic inhibitors of cathepsin c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1123033T1 true CY1123033T1 (el) | 2021-10-29 |
Family
ID=51535355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101154T CY1123033T1 (el) | 2014-09-12 | 2019-11-06 | Σπειροκυκλικοι αναστολεις της καθεψινης c |
Country Status (34)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011116282A2 (en) | 2010-03-19 | 2011-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nicotinic acetylcholine receptor agonists |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| EP3174879B1 (en) * | 2014-08-01 | 2018-07-18 | Boehringer Ingelheim International GmbH | Substituted oxetanes and their use as inhibitors of cathepsin c |
| UA118610C2 (uk) | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| US20200087390A1 (en) | 2016-12-21 | 2020-03-19 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| WO2018162312A1 (en) * | 2017-03-10 | 2018-09-13 | Basf Se | Spirocyclic derivatives |
| EP3749326A4 (en) * | 2018-02-07 | 2021-11-03 | Insmed Incorporated | CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA |
| FI3758708T3 (fi) | 2018-03-01 | 2025-02-18 | Astrazeneca Ab | (2s)-{(1s)-1-syano-2-[4-(3-metyyli-2-okso-2,3-dihydro-1,3-bentsoksatsol-5-yyli)fenyyli]etyyli}-1,4-oksatsepaani-2-karboksamidia käsittäviä farmaseuttisia koostumuksia |
| KR20210032431A (ko) | 2018-07-17 | 2021-03-24 | 인스메드 인코포레이티드 | 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드 |
| CN110256429B (zh) * | 2019-06-17 | 2021-06-22 | 广东药科大学 | 一种具有螺环结构的氨基嘧啶类化合物及其制备方法和应用 |
| CN110257504A (zh) * | 2019-06-30 | 2019-09-20 | 中南大学 | 一种难治性哮喘检测标记物的筛选方法及其应用 |
| CA3181285A1 (en) | 2020-07-20 | 2022-01-27 | Jessica BASSO | Methods for extracting neutrophil serine proteases and treating dipeptidyl peptidase 1-mediated conditions |
| CN114106005B (zh) * | 2020-08-26 | 2025-08-01 | 西藏海思科制药有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| JP2023550345A (ja) * | 2020-11-17 | 2023-12-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | ４－（５－（４－フルオロフェニル）－６－（テトラヒドロ－２ｈ－ピラン－４－イル）－１，５－ジヒドロピロロ［２，３－ｆ］インダゾール－７－イル）安息香酸の固体形態 |
| CA3199568A1 (en) * | 2020-12-04 | 2022-06-09 | Reistone Biopharma Company Limited | Small molecule inhibitor of cathepsin c and medicinal use thereof |
| CN114591315A (zh) * | 2020-12-04 | 2022-06-07 | 瑞石生物医药有限公司 | 一种组织蛋白酶c小分子抑制剂 |
| IL317570A (en) * | 2022-06-13 | 2025-02-01 | Alivexis Inc | Azacycloalkylcarbonyl cyclic amines and their use |
| WO2024008680A1 (en) | 2022-07-06 | 2024-01-11 | Chiesi Farmaceutici S.P.A. | Azetidine derivatives and use thereof as dipeptidyl peptidase 1 inhibitors |
| WO2024088307A1 (zh) * | 2022-10-26 | 2024-05-02 | 上海壹迪生物技术有限公司 | 一种新型肽基腈类化合物及其应用 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025214464A1 (en) * | 2024-04-12 | 2025-10-16 | Insmed Incorporated | Crystalline forms of (s) -n- (1-cyano-2- (2-fluoro-4- (1' - (oxetan-3-yl) -3h-spiro [isobenzofuran-1, 4' -piperidin] -6-yl) phenyl) ethyl) -2-azabicyclo [2.2.2] octane-1-carboxamide |
| US20260060930A1 (en) | 2024-08-27 | 2026-03-05 | Boehringer Ingelheim International Gmbh | New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4125727A (en) | 1976-10-18 | 1978-11-14 | American Cyanamid Company | Method of preparing imidazoisoindolediones |
| GB8922355D0 (en) | 1989-10-04 | 1989-11-22 | British Telecomm | Sealing gland |
| GEP20012487B (en) | 1998-09-16 | 2001-07-25 | Merab Lomia | Use of Chemical Agent 5-carbarnoyl-5H-Dibenz (b,f) azepin, its Derivatives and Analogues by New Purpose |
| US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
| JP4365094B2 (ja) | 2001-03-02 | 2009-11-18 | メルク フロスト カナダ リミテツド | カテプシンシステインプロテアーゼ阻害薬 |
| TW200306189A (en) | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| WO2004110988A1 (en) | 2003-06-18 | 2004-12-23 | Prozymex A/S | Protease inhibitors |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| WO2006096807A1 (en) | 2005-03-08 | 2006-09-14 | Janssen Pharmaceutica N.V. | Aza-bridged-bicyclic amino acid derivatives as alpha 4 integrin antagonists |
| MX341849B (es) * | 2006-06-01 | 2016-09-05 | Sanofi Aventis | Nitrilos espirociclicos como inhibidores de proteasa. |
| WO2008047544A1 (en) | 2006-09-28 | 2008-04-24 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| WO2009047829A1 (ja) | 2007-10-12 | 2009-04-16 | Fujitsu Limited | Ｉｐ電話自動試験システム及び方法 |
| KR20100098683A (ko) | 2007-12-12 | 2010-09-08 | 아스트라제네카 아베 | 펩티딜 니트릴, 및 디펩티딜 펩티다제 ｉ 억제제로서의 그의 용도 |
| AU2010244218B2 (en) | 2009-05-07 | 2012-07-19 | Astrazeneca Ab | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| WO2010142985A1 (en) | 2009-06-10 | 2010-12-16 | Astrazeneca Ab | Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761 |
| WO2012119941A1 (en) | 2011-03-04 | 2012-09-13 | Prozymex A/S | Peptidyl nitrilcompounds as peptidase inhibitors |
| US8999975B2 (en) | 2011-09-19 | 2015-04-07 | Boehringer Ingelheim International Gmbh | Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C |
| CN104379559B (zh) | 2012-04-27 | 2016-11-09 | 葛兰素集团有限公司 | 化合物 |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| BR112014029161A2 (pt) | 2012-05-22 | 2017-06-27 | Genentech Inc | benzamidas n-substituídas e seu uso no tratamento de dor |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| EA030253B1 (ru) | 2012-09-28 | 2018-07-31 | Кэнсэр Ресерч Текнолоджи Лимитед | Азахиназолиновые ингибиторы атипичной протеинкиназы c |
| EP2908806A1 (en) * | 2012-10-09 | 2015-08-26 | Boehringer Ingelheim International GmbH | Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets |
| CN105102432B (zh) | 2012-10-15 | 2019-01-04 | Epizyme股份有限公司 | 经取代的苯化合物 |
| JP6466335B2 (ja) | 2012-10-16 | 2019-02-06 | ヤンセン ファーマシューティカ エヌ．ベー． | ＲＯＲ−γ−Ｔのメチレン連結キノリニルモジュレーター |
| JP6359546B2 (ja) | 2012-11-01 | 2018-07-18 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ阻害薬としての三環式縮合チオフェン誘導体 |
| CA2895808A1 (en) | 2012-12-21 | 2014-06-26 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| SMT201800230T1 (it) | 2012-12-21 | 2018-07-17 | Plexxikon Inc | Composti e metodi per la modulazione della chinasi e loro indicazioni |
| US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
| WO2014140091A1 (en) * | 2013-03-14 | 2014-09-18 | Boehringer Ingelheim International Gmbh | Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c |
| AU2014230814B2 (en) | 2013-03-14 | 2017-12-21 | Boehringer Ingelheim International Gmbh | Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C |
| TWI599567B (zh) | 2013-03-14 | 2017-09-21 | 健生藥品公司 | Ｐ２ｘ７調節劑 |
| JO3383B1 (ar) | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| KR20150131224A (ko) | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| US20140275082A1 (en) | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| PE20151593A1 (es) | 2013-03-14 | 2015-11-05 | Newlink Genetics Corp | Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano |
| DK3137136T3 (en) * | 2014-04-29 | 2018-07-23 | Carebay Europe Ltd | DEVICE FOR ADJUSTING DEADLINE DEPTH |
| EP3164272A1 (en) | 2014-07-03 | 2017-05-10 | Bridgestone Americas Tire Operations, LLC | Sidewall decoration on rim guard |
| TR201820050T4 (tr) | 2014-09-12 | 2019-01-21 | Glaxosmithkline Ip No 2 Ltd | Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri. |
| UA118610C2 (uk) * | 2014-09-12 | 2019-02-11 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Спіроциклічні інгібітори катепсину c |
| AR101696A1 (es) | 2014-09-12 | 2017-01-04 | Lilly Co Eli | Compuestos de azetidiniloxifenilpirrolidina |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
-
2015
- 2015-09-08 UA UAA201703350A patent/UA118610C2/uk unknown
- 2015-09-08 CN CN201580048467.6A patent/CN107074870B/zh active Active
- 2015-09-08 BR BR112017003433-6A patent/BR112017003433B1/pt active IP Right Grant
- 2015-09-08 MX MX2017003156A patent/MX367316B/es active IP Right Grant
- 2015-09-08 PT PT157575234T patent/PT3191487T/pt unknown
- 2015-09-08 AP AP2017009733A patent/AP2017009733A0/en unknown
- 2015-09-08 CN CN201810030066.3A patent/CN108047240B/zh active Active
- 2015-09-08 ES ES15757523T patent/ES2749009T3/es active Active
- 2015-09-08 EP EP15757523.4A patent/EP3191487B1/en active Active
- 2015-09-08 SI SI201530977T patent/SI3191487T1/sl unknown
- 2015-09-08 AU AU2015314355A patent/AU2015314355B2/en active Active
- 2015-09-08 HR HRP20191756TT patent/HRP20191756T1/hr unknown
- 2015-09-08 RS RSP20191350 patent/RS59444B1/sr unknown
- 2015-09-08 PL PL15757523T patent/PL3191487T3/pl unknown
- 2015-09-08 JP JP2017513658A patent/JP2017526716A/ja not_active Ceased
- 2015-09-08 MX MX2019009695A patent/MX378099B/es unknown
- 2015-09-08 DK DK15757523T patent/DK3191487T3/da active
- 2015-09-08 PE PE2017000400A patent/PE20170438A1/es unknown
- 2015-09-08 WO PCT/EP2015/070449 patent/WO2016038007A1/en not_active Ceased
- 2015-09-08 MY MYPI2017000213A patent/MY188382A/en unknown
- 2015-09-08 SG SG11201701633SA patent/SG11201701633SA/en unknown
- 2015-09-08 HU HUE15757523A patent/HUE047208T2/hu unknown
- 2015-09-08 CA CA2960916A patent/CA2960916C/en active Active
- 2015-09-08 KR KR1020177009993A patent/KR102510588B1/ko active Active
- 2015-09-08 EA EA201790576A patent/EA031376B1/ru not_active IP Right Cessation
- 2015-09-08 EP EP19155235.5A patent/EP3511331A1/en not_active Withdrawn
- 2015-09-08 LT LTEP15757523.4T patent/LT3191487T/lt unknown
- 2015-09-08 NZ NZ728684A patent/NZ728684A/en unknown
- 2015-09-10 US US14/849,710 patent/US9540373B2/en not_active Ceased
- 2015-09-11 TW TW104130165A patent/TWI687424B/zh active
-
2016
- 2016-11-29 US US15/362,949 patent/US9879026B2/en active Active
-
2017
- 2017-01-24 IL IL250262A patent/IL250262B/en active IP Right Grant
- 2017-02-23 CL CL2017000432A patent/CL2017000432A1/es unknown
- 2017-03-07 CO CONC2017/0002268A patent/CO2017002268A2/es unknown
- 2017-03-09 SA SA517381064A patent/SA517381064B1/ar unknown
- 2017-03-10 PH PH12017500453A patent/PH12017500453B1/en unknown
- 2017-11-30 US US15/827,433 patent/USRE47636E1/en active Active
- 2017-12-22 JP JP2017246001A patent/JP6360961B2/ja active Active
-
2018
- 2018-11-14 HK HK18114501.3A patent/HK1255362A1/zh unknown
-
2019
- 2019-11-06 CY CY20191101154T patent/CY1123033T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125214T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| MX2019009695A (es) | Inhibidores espirociclicos de catepsina c. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2018000396A (es) | Compuestos aza sustituidos como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak-4). | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201691354A1 (ru) | Терапевтические ингибирующие соединения | |
| BR112017013440A2 (pt) | compostos de isoquinolina para o tratamento de hiv | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| EA201790271A1 (ru) | Ингибиторы гликозидазы | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| MX380250B (es) | Compuestos farmacéuticos inhibidores de cinasa chk-1. | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| MX2019006893A (es) | Inhibidores heterociclicos de mct4. | |
| BR112016018062A8 (pt) | compostos terapêuticos, composição farmacêutica e usos | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
| EA201691481A1 (ru) | ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| EA201690783A1 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| EA201791174A1 (ru) | Антимикотическое соединение | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. |